Log in

ANI Pharmaceuticals Stock Forecast, Price & News

+0.52 (+1.74 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $30.36
50-Day Range
MA: $30.41
52-Week Range
Now: $30.36
Volume165,992 shs
Average Volume108,701 shs
Market Capitalization$373.88 million
P/E RatioN/A
Dividend YieldN/A
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Read More
ANI Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.09 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANIP
Previous SymbolNASDAQ:BPAX



Sales & Book Value

Annual Sales$206.55 million
Cash Flow$8.65 per share
Book Value$17.59 per share


Net Income$6.09 million


Market Cap$373.88 million
Next Earnings Date11/4/2020 (Estimated)
+0.52 (+1.74 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

How has ANI Pharmaceuticals' stock price been impacted by Coronavirus?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANIP stock has decreased by 20.7% and is now trading at $30.36.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of ANI Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ANI Pharmaceuticals

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ANI Pharmaceuticals

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the Zacks' consensus estimate of $0.57 by $0.12. The specialty pharmaceutical company had revenue of $48.47 million for the quarter, compared to the consensus estimate of $45.70 million. ANI Pharmaceuticals had a positive return on equity of 20.11% and a negative net margin of 10.27%. During the same quarter in the previous year, the company earned $1.44 earnings per share.
View ANI Pharmaceuticals' earnings history

What price target have analysts set for ANIP?

3 equities research analysts have issued 12-month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $40.00 to $58.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $46.00 in the next year. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a increase in short interest in August. As of August 14th, there was short interest totaling 637,900 shares, an increase of 15.6% from the July 30th total of 552,000 shares. Based on an average daily trading volume, of 134,000 shares, the days-to-cover ratio is currently 4.8 days. Currently, 6.7% of the company's stock are sold short.
View ANI Pharmaceuticals' Short Interest

Who are some of ANI Pharmaceuticals' key competitors?

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA), AbbVie (ABBV), Alibaba Group (BABA), Broadcom (AVGO), Intel (INTC), NVIDIA (NVDA) and Cisco Systems (CSCO).

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:
  • Mr. Arthur S. Przybyl, Pres, CEO & Director (Age 62)
  • Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (2.44%), Thompson Siegel & Walmsley LLC (2.42%), Goldman Sachs Group Inc. (2.22%), Assenagon Asset Management S.A. (1.16%), Bank of New York Mellon Corp (0.86%) and Russell Investments Group Ltd. (0.81%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, David Nash, James G Marken, Meridian Venture Partners Ii L, Patrick D Walsh, Robert W Schrepfer and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals

Which institutional investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, Bank of Montreal Can, Tudor Investment Corp Et Al, Man Group plc, Goldman Sachs Group Inc., Principal Financial Group Inc., and Principal Financial Group Inc..
View insider buying and selling activity for ANI Pharmaceuticals

Which institutional investors are buying ANI Pharmaceuticals stock?

ANIP stock was acquired by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Federated Hermes Inc., Assenagon Asset Management S.A., WINTON GROUP Ltd, Two Sigma Advisers LP, Engineers Gate Manager LP, Aigen Investment Management LP, and UBS Group AG. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash, Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $30.36.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $373.88 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.